Young woman using inhaler against asthma

Image source: Adobe Stock/Pixel-Shot

News • Enhancing lung defense

An inhalable ‘SHIELD’ against Covid-19 and flu viruses

Researchers have developed an inhalable powder that could protect lungs and airways from viral invasion by reinforcing the body’s own mucosal layer. The powder, called Spherical Hydrogel Inhalation for Enhanced Lung Defense, or SHIELD, reduced infection in both mouse and non-human primate models over a 24-hour period, and can be taken repeatedly without affecting normal lung function.

The study appears in Nature Materials

“The idea behind this work is simple – viruses have to penetrate the mucus in order to reach and infect the cells, so we’ve created an inhalable bioadhesive that combines with your own mucus to prevent viruses from getting to your lung cells,” says Ke Cheng, corresponding author of the paper describing the work. “Mucus is the body’s natural hydrogel barrier; we are just enhancing that barrier.” Cheng is the Randall B. Terry, Jr. Distinguished Professor in Regenerative Medicine at North Carolina State University’s College of Veterinary Medicine and a professor in the NC State/UNC-Chapel Hill Joint Department of Biomedical Engineering. 

The inhalable powder microparticles are composed of gelatin and poly(acrylic acid) grafted with a non-toxic ester. When introduced to a moist environment – such as the respiratory tract and lungs – the microparticles swell and adhere to the mucosal layer, increasing the “stickiness” of the mucus. The effects are most potent during the first eight hours after inhalation. SHIELD biodegrades over a 48-hour period, and is completely cleared from the body.

It works like an ‘invisible mask’ for people in situations where masking is difficult, for example during heavy exercise, while eating or drinking, or in close social interactions

Ke Cheng

In a mouse model, SHIELD blocked SARS-CoV-2 pseudovirus particles with 75% efficiency four hours after inhalation, which fell to 18% after 24 hours. The researchers found similar results when testing against pneumonia and H1N1 viruses. In a non-human primate model of both the original and Delta SARS-CoV-2 variants, SHIELD-treated subjects had reduced viral loads – from 50 to 300-fold less than control subjects – and none of the symptoms commonly associated with infection in primates, such as lung inflammation or fibrosis. Since primates do not exhibit the same symptoms of infection as humans, viral load is the standard marker used to determine exposure. 

The researchers also looked at potential toxicity both in vitro and in vivo: 95% of cell cultures exposed to a high concentration (10 mg ml-1) of SHIELD remained healthy, and mice who were given daily doses for two weeks retained normal lung and respiratory function. “SHIELD is easier and safer to use than other physical barriers or anti-virus chemicals,” Cheng says. “It works like an ‘invisible mask’ for people in situations where masking is difficult, for example during heavy exercise, while eating or drinking, or in close social interactions. People can also use SHIELD on top of physical masking to have better protection. But the beauty of SHIELD is that it isn’t necessarily limited to protecting against Covid-19 or flu. We’re looking at whether it could also be used to protect against things like allergens or even air pollution – anything that could potentially harm the lungs.” 

The study is supported by the National Institutes of Health, the American Heart Association, and special funding from the NC State Provost’s Office. The researchers have filed a patent and are working on FDA approval for human use. 

Source: North Carolina State University


Read all latest stories

Related articles


News • Dangerous immune response

New insight on severe virus attacks on the lungs

In some cases, immune cells in the lungs can contribute to worsening a virus attack. In a new study, researchers at Karolinska Institutet describe how different kinds of immune cells, called…


Article • Re-evaluation of the coronavirus disease

COVID-19: A tale of two conditions

The SARS CoV-2 virus which causes COVID-19 may have been named prematurely. As more has become known about the infection, the severe disease does not appear to be a respiratory syndrome at all.…


News • Pilot clinical trial

China to test targeted therapy for COVID-19

A University of British Columbia (UBC) researcher is part of an international team working with a biotechnology company on a pilot clinical trial of a potential new treatment for patients with severe…

Related products

Subscribe to Newsletter